DentalMonitoring Startup Diligence Report
The diligence case turns on whether DentalMonitoring’s combination of regulatory status, image-data scale, workflow integrations, SmartSTL, and global GTM execution can translate into durable, profitable, and defensible software economics once audited financials, retention cohorts, cap-table terms, and legal / regulatory operating detail are reviewed.
DentalMonitoring Startup Diligence Report
DentalMonitoring appears to be a real, scaled private digital-health software company with a credible regulated remote-monitoring product stack, meaningful workflow breadth, global commercial reach, and visible financing support, but the public record is materially weaker on audited financial quality, capitalization, customer concentration, supplier economics, and downside legal schedules.
Sponsor-stated profitability and scale claims are public, but audited revenue quality, margins, cash, debt, and backlog are not.
Diligence request: Obtain audited financials, management accounts, cash / debt detail, margin bridge, and revenue-quality diagnostics.
Public sources identify named practitioner references but not ARR concentration, churn, NRR, or customers above 5% of revenue.
Diligence request: Obtain top-customer schedules, churn / NRR cohorts, contract terms, and renewal calendars.
Public financing amounts do not reveal post-money valuation, ownership percentages, preferences, debt, or employee dilution.
Diligence request: Request the fully diluted cap table, financing documents, debt schedule, and current valuation support.
Grin, CandidPro, and uLab show adjacent capabilities that can compress differentiation or re-route workflows away from DentalMonitoring.
Diligence request: Benchmark feature parity, pricing concessions, customer win/loss data, and competitor-driven churn.
The regulated-software model requires ongoing FDA / EU compliance, post-market surveillance, and country-specific claims discipline.
Diligence request: Review technical files, PMCF / PMS records, complaint logs, CAPAs, and country-by-country regulatory status.
DentalMonitoring handles patient images, messaging, and cross-border workflows, making privacy and cybersecurity central legal exposures.
Diligence request: Request security certifications, incident logs, DPAs, data-flow maps, breach history, and privacy-governance materials.
Many public commercial-outcome claims come from company-curated evidence, testimonials, or partner releases rather than independent benchmarking.
Diligence request: Request raw before/after KPI studies, independent customer references, and unbiased outcome measurement by cohort.
DentalMonitoring’s visible PMS, manufacturer, and analytics ecosystem could create meaningful dependency on third-party integrations and partner economics.
Diligence request: Review partner contracts, SLAs, usage depth, concentration, and contingency plans for integration breakage.
Public sources verify the company identity, a limited financing history, and sponsor-stated profitability and adoption signals, but they do not provide audited revenue quality, valuation support, cap-table detail, debt, or forecasts.
not publicly verifiable confidence: low
Reviewed public sources offer only sponsor-stated profitability and adoption signals; audited income statements, balance sheets, cash flows, backlog, and AR aging were not publicly available.
| metric | public value | verification status | diligence request |
|---|---|---|---|
| Operational profitability | Company-sponsored release says operational profitability was achieved in 2025. | partially_verified | Audited P&L, EBITDA bridge, cash flow, stock-based compensation, and one-off regulatory / financing costs. |
| Adoption scale used as financial proxy | 8,000+ providers and 2M+ patients were publicly claimed in company materials. | partially_verified | Paid customer count, revenue per provider, gross retention, NRR, and cohort monetization by region. |
| Revenue / ARR / gross margin / cash | No audited revenue, ARR, gross margin, cash, debt, backlog, or AR aging were publicly disclosed in reviewed sources. | not_publicly_verifiable | Three years of audited financials, monthly management accounts, backlog, AR aging, cash, debt, and covenant packages. |
| Pricing, conversion, CAC, and payback | Reviewed product pages did not show public numeric pricing or conversion metrics. | not_publicly_verifiable | Master price book, regional discount policy, pipeline conversion, CAC, payback, and sales-efficiency reporting. |
Public operating claims help frame scale, but they are not a substitute for auditable financial diligence.
not publicly verifiable confidence: low
Public sources show growth drivers such as regulatory approvals, integrations, SmartSTL, and geographic expansion, but no board-approved projections or unit-economic assumptions were publicly available.
not publicly verifiable confidence: low
Public sources identify the French SAS legal entity and some investors, but do not disclose shares outstanding, option pool, debt, or ownership percentages.
| stakeholder or class | public position | diligence caveat |
|---|---|---|
| Dental Monitoring SAS | French SAS legal entity, RCS 824 001 259, privately held, headquarters at 75 rue de Tocqueville, Paris. | Shares outstanding, shareholder register, debt, and beneficial ownership are not publicly disclosed. |
| Founding / management group | Founded in 2014 by a team of industry professionals; Philippe Salah is publicly identified as CEO and co-founder. | Founder ownership, vesting, voting rights, and secondary liquidity remain private. |
| Historical institutional investor | About Us timeline states a third round backed by Vitruvian Partners for €45M. | Round date, security type, liquidation preference, and current ownership percentage are not public. |
| 2026 incoming investors | Lazard Elaia Capital and ISALT / FST were named in the $100M investment announcement. | Instrument type, dilution, board rights, and resulting cap-table changes were not disclosed. |
| Employee equity, options, warrants, and debt | Not publicly disclosed in reviewed sources. | Required to assess dilution, retention, and enterprise-to-common equity value. |
This table is intentionally incomplete because the checklist items require private cap-table and financing documents.
partially verified confidence: medium
The reviewed public financing record is limited to a historical €45M Vitruvian-backed round and a 2026 $100M investment announcement; post-money valuation and accounting policy detail remain private.
| date | event | investors or round | amount | source note |
|---|---|---|---|---|
| Historical timeline entry (date not stated on current page) | Third fundraising round | Vitruvian Partners-backed financing | €45M | About Us timeline discloses a completed third round; the currently reviewed page does not show the round date or post-money valuation. |
| 2026-02-10 | Growth capital investment | Lazard Elaia Capital and ISALT / Fonds Stratégique des Transitions | $100M | Company-sponsored financing release; investment amount is public, but valuation, ownership %, and instrument terms were not disclosed. |
| Current public review | Post-money valuation / share price support | Not publicly disclosed in reviewed sources | not_publicly_verifiable | Cap table, preference stack, and board valuation support were not public. |
Public financing history is sparse relative to the diligence checklist and does not support a current valuation view on its own.
The chart uses native-currency amount labels; it is not a valuation curve because post-money support was not public.
Public company materials support a real product suite spanning remote monitoring, lead qualification, analytics, SmartSTL, and hardware, but pricing transparency, product-level economics, and country-specific commercial availability remain limited.
partially verified confidence: medium
Reviewed public pages verify multiple modules—DentalMonitoring core, DM Engage, DM Insights, SmartSTL, and ScanBox pro / DM App—but do not disclose numeric pricing, unit economics, or product-by-product profitability.
| product | audience | key features | public evidence | verification status |
|---|---|---|---|---|
| DentalMonitoring core platform | Orthodontists and dentists | AI-powered remote monitoring, 130+ oral observations, all treatment phases and appliance brands, patient messaging, appointment optimization. | Core product page and LinkedIn about description. | verified |
| DM Engage | Practices qualifying new or returning patients | AI-assisted online assessment, photo capture, report generation, HIPAA/GDPR-compliant video consultations. | DM Engage product page. | verified |
| DM Insights | Multi-provider or analytics-focused practices | Benchmarking, message analytics, monitoring status, conversion-rate views, patient and practice activity trends. | DM Insights page. | verified |
| SmartSTL | Practitioners handling refinements, mid-course corrections, retention, or relapse | Remote updated STL generation using initial IOS, stage file, and DM scans; no extra in-practice scan needed for many workflows. | SmartSTL page and FDA press release. | verified |
| ScanBox pro + DM App | Patients scanning from home under HCP supervision | Portable proprietary hardware, smartphone-guided scans, high-quality intraoral views, all-brand use, support for patients over 6. | ScanBox release, IFU page, and FDA release. | verified |
| Vision / SmileMate (legacy or adjacent workflow modules) | Practices handling simulation, engagement, and pre-treatment workflow | Smile simulation and engagement / triage modules referenced in public company materials and privacy policy service definitions. | About Us history, ScanBox release, and privacy policy. | partially_verified |
The current website emphasizes DentalMonitoring, DM Engage, DM Insights, SmartSTL, and patient workflows; legacy products still appear in some public documents.
| solution | audience | pricing public signal | commercial packaging note | verification status |
|---|---|---|---|---|
| DentalMonitoring core platform | Orthodontists and dentists | Book a demo; no numeric public pricing found on reviewed page. | Platform plus patient app and proprietary scan hardware workflow. | not_publicly_verifiable |
| DM Engage | Practices qualifying treatment leads | Book a demo; no numeric public pricing found on reviewed page. | Assessment and consultation module positioned as conversion tool. | not_publicly_verifiable |
| Grin | Dental and orthodontic practices | Page states “transparent, affordable pricing” without numeric pricing. | Virtual-care ecosystem with FDA-registered scope, care specialists, and AI treatment tracking. | not_publicly_verifiable |
| CandidPro | General dentists | Book a live personalized discussion; no numeric public pricing found on reviewed page. | Clear aligner system with orthodontist support, at-home monitoring, and patient-support services. | not_publicly_verifiable |
| uLab Systems | Orthodontic and dental practices | Bundle and a la carte options are described, but no numeric pricing is public on reviewed page. | Emphasis on aligners, retainers, indirect bonding, and in-office manufacturing flexibility. | not_publicly_verifiable |
Numeric pricing likely exists in sales materials or contracts, but not in the reviewed public pages.
Public sources show named practitioner references, patient-survey data, and a broad partner ecosystem, but they do not reveal top-customer revenue, churn, customer concentration, or supplier spend.
partially verified confidence: medium
Reviewed public sources provide named practitioner references and study cohorts rather than a top-15 customer schedule by revenue.
| customer or practice | source | use case | scale or outcome | verification status |
|---|---|---|---|---|
| Guy Deeming orthodontic practice group (north-east England) | Dentistry Online interview | Virtual practice model with all aligner patients on DentalMonitoring and appointment-on-demand workflow. | Roughly 1,800-2,000 NHS starts and around 1,000 private starts annually; tens of hours saved per month. | partially_verified |
| Dr. Grant Duncan practice | DM Engage page | Virtual qualification and conversion of new patients through DM Engage. | Doctor testimonial says the practice picked up 33% more appointments than it normally would have. | partially_verified |
| Dr. Dabney single-doctor practice | Evidence page | Expanding appointment intervals and improving value per visit. | Braces value per visit $384 on 15.4 visits; aligner value per visit $779 on 5.6 visits. | partially_verified |
| Dr. Audrey Chokron case study | Evidence page | Complex aligner case managed with AI-powered remote monitoring. | 22-month treatment reportedly involved 90 DM scans and only seven in-office visits. | partially_verified |
| Global patient survey cohort | Evidence page | Patient-experience and satisfaction study across multiple countries. | Survey of 2,248 patients in 12 countries; 86% satisfied and 88% found DM easy to use. | partially_verified |
These public references are useful for qualitative diligence, but they do not replace a top-15 revenue schedule or customer-reference calls.
partially verified confidence: medium
Public evidence supports a meaningful workflow ecosystem with PMS, aligner, and analytics partners, but partner economics and concentration are not public.
| partner | nature | public evidence | gap or caveat |
|---|---|---|---|
| Gaidge | Practice intelligence and business analytics pilot | 2021 PR says 100+ practices would be invited to pilot a combined DentalMonitoring + Gaidge smart-practice program. | Pilot economics, conversion lift, retention, and current status are not public. |
| Dolphin Management | Practice-management integration | Practitioners can access the DentalMonitoring patient card and start, stop, or pause monitoring inside Dolphin. | Commercial terms, implementation volume, and churn are not public. |
| Spark Clear Aligner System | Manufacturer / SmartSTL workflow integration | Practitioners can request mid-course corrections or refinements via Spark Approver Software using SmartSTL. | Revenue share, usage penetration, and exclusivity are not public. |
| Orthalis | Practice-management integration | Orthalis integration supports patient-profile updates, monitoring control, and automatic scheduling based on AI-detected clinical needs. | Contractual SLAs and adoption levels are not public. |
| OrthoBridge | Practice-management and messaging integration | Integration allows profile creation, scan management, monitoring control, and patient messaging. | Commercial scope and renewal data are not public. |
| Cloud 4 Ortho, OrthoNovo, DentoNovo, OrthoADVANCE, Software 4 Dentists, GreyFinch, TIO International, Dentitek | Workflow / practice-management partner set | Integration page lists these platforms as systems that “speak with” DentalMonitoring for patient and monitoring workflows. | Partner-by-partner economics, implementation depth, and materiality are not public. |
Public evidence shows breadth of workflow integration, not the size or durability of partner economics.
Coordinates are analyst-coded from reviewed public materials rather than disclosed partner economics.
not publicly verifiable confidence: low
Reviewed public sources did not disclose customer-level revenue, customers above 5% of revenue, churn, or NRR.
not publicly verifiable confidence: low
No significant severed customer, partner, or supplier relationships were verified from reviewed public sources, but public pages do not provide a termination schedule.
partially verified confidence: low
Public sources reveal infrastructure and workflow dependencies such as AWS, app stores, ScanBox hardware, and SaaS counterparties, but not supplier spend or concentration.
| supplier or dependency | role | public evidence | concentration or operational risk |
|---|---|---|---|
| Amazon Web Services (AWS) | Website hosting and data-processing infrastructure | Privacy policy says the corporate website is hosted in AWS cloud services with servers in different locations; AWS is described as ISO 27001 and HDS compliant. | Cloud concentration, data-residency, and contractual resilience need direct vendor diligence. |
| Smartphones + Apple / Google app distribution | Patient scan capture and mobile application distribution | Product pages and privacy policy describe smartphone-based scanning and list the Dental Monitoring app on the iOS App Store and Google Play. | Mobile platform policy changes, app-store approval rules, and device-quality variation can affect adoption and clinical image quality. |
| ScanBox pro proprietary hardware | Physical capture accessory used with patient smartphones | ScanBox pro release and product pages describe a portable proprietary device paired with the DM app. | Manufacturing partners, component sourcing, field failure, and replacement economics are not public. |
| BambooHR | HR and recruiting process infrastructure | Privacy policy identifies BambooHR in joint-controller language and the careers page uses BambooHR-hosted job postings. | Not product-critical, but it signals SaaS dependence in people operations and cross-border data processing. |
No public supplier spend, cloud commitments, or hardware manufacturing counterparties were found.
Public feature disclosures suggest DentalMonitoring competes credibly on regulated remote monitoring and workflow breadth, but faces capable adjacent rivals in virtual care, aligners, and manufacturing-centric workflows.
partially verified confidence: medium
The reviewed public landscape places DentalMonitoring against Grin, CandidPro, and uLab across remote care, aligner systems, and workflow-manufacturing control.
| competitor | segment | public product signal | product overlap | differentiator or gap | source note |
|---|---|---|---|---|---|
| DentalMonitoring | AI-powered remote monitoring and workflow software for orthodontics / dentistry | FDA De Novo, EU-MDR, 130+ oral observations, SmartSTL, DM Engage, DM Insights, and broad PMS integrations. | Target company reference point | Strong public regulatory and integration story, but public pricing and customer concentration remain opaque. | Company product, regulatory, and integration pages. |
| Grin | Virtual care and remote monitoring ecosystem | FDA-registered Grin Scope, Grin Care Specialists, and AI 3D Treatment Tracker. | High overlap on remote monitoring and patient scanning. | Strong virtual-care tooling; public pages reviewed did not show the same FDA De Novo / EU-MDR software claims as DentalMonitoring. | Grin company pages. |
| CandidPro | Clear aligner system with at-home monitoring and orthodontist support | At-home monitoring, after-hours patient support, and claim that 90% of cases finish with one or fewer refinements. | Moderate overlap on remote monitoring and patient support. | More vertically aligned around its own clear aligner system and general-dentist channel. | CandidPro provider platform page. |
| uLab Systems | Aligner design, manufacturing, and in-office workflow platform | In-office manufacturing, aligners + retainers + indirect bonding, hybrid/combo workflow control. | Partial overlap through workflow control and monitoring-adjacent aligner tracking. | Stronger public emphasis on manufacturing control and practice branding, weaker public emphasis on regulated remote monitoring. | uLab Systems homepage. |
This matrix is limited to competitors and product signals that were directly reviewable from public websites.
| axis | dentalmonitoring | grin | candidpro | ulab | evidence |
|---|---|---|---|---|---|
| Regulatory validation for remote monitoring software | high | medium | medium | low | DentalMonitoring publicly shows FDA De Novo and EU-MDR; Grin highlights FDA-registered hardware; CandidPro emphasizes provider support and at-home monitoring; uLab emphasizes aligner workflow. |
| Remote monitoring depth | high | high | medium | low | DentalMonitoring and Grin both center scanning and ongoing monitoring; CandidPro includes at-home monitoring within its aligner system; uLab emphasizes treatment design and manufacturing. |
| Workflow breadth / integrations | high | medium | medium | medium | DentalMonitoring publicly lists a broad PMS / manufacturer integration set and analytics modules; peers highlight narrower workflow sets on the pages reviewed. |
| Appliance agnosticism | high | high | low | medium | DentalMonitoring and Grin both publicly emphasize broad appliance compatibility; CandidPro is centered on its own clear aligner system; uLab emphasizes flexible aligner manufacturing and hybrid cases. |
| Public numeric pricing transparency | low | low | low | low | Reviewed public pages did not provide numeric pricing for any of the compared platforms. |
Scores are analyst-coded from reviewed public feature disclosures and do not reflect win/loss or customer-satisfaction data.
Public GTM evidence points to a direct-sales, implementation-led, and ecosystem-enabled model amplified by DM Engage, evidence marketing, and global expansion hiring, but sales productivity and budget efficiency remain private.
partially verified confidence: medium
Public sources support a doctor-centric GTM model built around demos, DM Engage, partner workflows, clinical implementation, and evidence-led marketing.
| channel or motion | region | public evidence | gap or caveat |
|---|---|---|---|
| Direct demo-led clinical sales | Global public footprint | Product pages use demo CTAs; About Us and LinkedIn list offices/support in Paris, Austin, London, Hong Kong, Sydney, and Japan-related support. | Pipeline, conversion, quotas, and sales productivity are not public. |
| DM Engage lead qualification and remote consultations | Virtual / cross-border where permitted | DM Engage lets leads submit photos, receive AI-generated reports, and book video or in-practice appointments. | Lead volume, CAC, close rate, and funnel conversion are not public. |
| Workflow / ecosystem partnerships | US and Europe visible from named partners | Integration page and Gaidge / Spark public references show partner-enabled workflow distribution. | Partner-sourced pipeline and revenue contribution are not public. |
| Evidence marketing, white papers, and case studies | Global public marketing library | Evidence page compiles case studies, practitioner white papers, surveys, and literature summaries. | Many outcomes are sponsor-generated or curated and should not be treated as independently benchmarked marketing ROI. |
| Field implementation and expansion hiring | US, France, Nordics, Germany, Portugal, Turkey, Belgium, Netherlands | Careers page lists account executives, product specialists, implementation specialists, and clinical deployment roles across multiple territories. | Territory attainment, payback period, and channel-mix economics are not public. |
Public GTM evidence implies a hybrid of direct sales, implementation, and partner-enabled workflow adoption.
| signal | public metric | implication | source |
|---|---|---|---|
| LinkedIn audience | 33,007 followers | Meaningful professional-brand reach into the dental / orthodontic ecosystem. | LinkedIn company page |
| Patient-app social proof | Nearly 14,500 reviews and a 4.9-star rating claimed on DM Difference page | Useful patient-experience marketing asset, although self-reported and not independently verified. | DM Difference page |
| Patient-experience evidence | 2,248-patient survey across 12 countries | Supports global patient-marketing narrative around convenience and reassurance. | Evidence page |
| Partner proof-points | 11+ PMS / workflow integrations plus Spark and a 100+ practice Gaidge pilot | Ecosystem breadth can lower switching friction and create co-marketing opportunities. | Integration page and Gaidge PR |
| Commercial hiring signal | 14 public sales / implementation openings in multiple territories | Suggests active geographic expansion and field-support investment. | Careers page |
These are public demand signals, not proof of efficient customer acquisition.
partially verified confidence: medium
Public evidence of major customers is testimonial and case-study based rather than contract-based, leaving revenue importance and pipeline conversion unproven.
partially verified confidence: medium
The principal public avenues appear to be DM Engage, direct demos, events / content, and workflow partner integrations.
not publicly verifiable confidence: low
Territory hiring shows a field-selling and implementation footprint, but quotas, attainment, sales-cycle length, and compensation are not public.
not publicly verifiable confidence: low
The company has public evidence of recent financing and self-reported operational profitability, but no public marketing budget or budget-versus-plan reporting.
Public evidence supports substantial AI, imaging, and workflow R&D activity, but R&D spend, model-performance governance, and detailed roadmap ownership remain private.
partially verified confidence: medium
Public R&D signals include named regulatory leadership, AI hiring in Paris and Brno, a new software development center, and a technical portfolio spanning vision, mobile, and integrations.
| name or role | role | public background or context | source note |
|---|---|---|---|
| Philippe Salah | CEO and co-founder | Publicly frames the company’s AI, virtual-care, and regulatory strategy; quoted across About Us, FDA, EU-MDR, and financing milestones. | About Us and press releases. |
| Arnaud Berthier | Director of Regulatory, Quality and Clinical Affairs | Quoted on the EU-MDR milestone, signaling a named regulatory / quality lead. | EU-MDR press release. |
| Lead Computer Vision (3D/Optimization) | Open Paris R&D role | Signals active investment in 3D optimization and computer-vision research. | Careers page. |
| Machine Learning Engineer | Open Paris R&D role | Signals ongoing ML hiring beyond leadership-level marketing claims. | Careers page. |
| Optical - Computer Vision Engineer | Open Paris R&D role | Supports the inference that image capture / imaging quality remains core to the roadmap. | Careers page. |
| ML / Python / Android / Java-Kotlin engineering roles | Open Paris and Brno technical roles | Shows the R&D effort spans models, backend, mobile, and production software rather than pure research. | Careers page. |
Reviewed public sources revealed only a partial named leadership roster; most technical evidence comes from hiring signals.
This is a partial public org chart, not a confirmed internal reporting structure.
partially verified confidence: medium
Public pipeline visibility includes SmartSTL rollout, ScanAssist-guided workflows, new development capacity, additional integrations, and expansion beyond orthodontics, but timing and cost-to-complete are private.
| project or capability | public status | expected timing | source | verification |
|---|---|---|---|---|
| SmartSTL North America rollout | Introduced to North American orthodontists after FDA De Novo approval. | 2024 onward; no detailed launch schedule public. | FDA De Novo press release and SmartSTL page | partially_verified |
| ScanAssist-guided weekly monitoring and clinical updates | Described as current functionality in company and LinkedIn materials. | Current | LinkedIn and EU-MDR press release | verified |
| DM Insights analytics expansion | Practice benchmarking, conversion-rate views, and monitoring analytics described as active product capability. | Current / iterative | DM Insights page | verified |
| Broader PMS / manufacturer / intra-oral scanning integrations | 2026 financing release says DentalMonitoring plans to expand integrations and partnerships across the orthodontic digital ecosystem. | Not publicly specified | Financing release and integration page | partially_verified |
| New software development center | 2026 financing release says a new software development center was recently launched. | Current as of 2026 release | Financing release | partially_verified |
| Expansion beyond orthodontics into broader dental applications | Management says DentalMonitoring will explore applying its AI and proprietary data to additional dental applications. | Forward-looking / no public milestone dates | Financing release | partially_verified |
Public pipeline visibility is stronger on direction than on dates, cost to complete, or launch quality.
Public sources reveal a global organization with visible hiring and a few named leaders, but they do not provide a full executive roster, compensation schedule, equity plan, or turnover history.
partially verified confidence: low
A high-level public org can be inferred from Philippe Salah and the functional groups on the careers page, but not a formal executive or board chart.
partially verified confidence: low
The public workforce picture is limited to a 400+ employees / 18 countries claim, a 544 LinkedIn employee-profile count, and current job postings across multiple functions and regions.
| metric | public value | evidence | date or region |
|---|---|---|---|
| Company careers claim | 400+ employees in 18 countries | Careers page | Page updated 2024-08-05 |
| LinkedIn employee-profile anchor | 544 employees; company-size bracket 501-1,000 | LinkedIn company page | Snapshot accessed 2026-06-10 |
| Customer Care openings | 2 open roles | Careers page | Sydney, NSW |
| Product & Software openings | 6 open roles | Careers page | Paris and Brno |
| R&D openings | 3 open roles | Careers page | Paris |
| Sales and implementation openings | 14 open roles | Careers page | US, France, Germany, Nordics, Belgium, Netherlands, Portugal, Turkey, Spain |
LinkedIn counts and careers counts use different methodologies and should not be treated as payroll-equivalent without reconciliation.
partially verified confidence: low
Philippe Salah and Arnaud Berthier are publicly identified in reviewed sources, but the broader senior-management roster remains incomplete.
| name | role | public biography | public source | note |
|---|---|---|---|---|
| Philippe Salah | CEO and co-founder | Public face of company strategy; quoted on AI mission, regulatory milestones, and financing expansion; associated with company since founding in 2014. | About Us and company press releases | Reviewed sources did not provide a full executive biography, prior roles, or board history. |
| Arnaud Berthier | Director of Regulatory, Quality and Clinical Affairs | Quoted on EU-MDR certification and public regulatory milestone framing. | EU-MDR press release | Reviewed sources did not provide a longer biography or tenure history. |
| Not publicly identified in reviewed sources | Finance leadership | Finance function is visible through open accounting roles, but a named CFO or finance executive was not identified. | Careers page | Management roster incomplete. |
| Not publicly identified in reviewed sources | Product / engineering leadership | Product and engineering hiring is public, but named product or CTO leadership was not surfaced in reviewed sources. | Careers page | Management roster incomplete. |
| Not publicly identified in reviewed sources | Commercial leadership | Territory hiring is visible, but named CRO / VP Sales leadership was not identified in reviewed public sources. | Careers page | Management roster incomplete. |
The checklist asks for executive biographies; public-source coverage was materially narrower than that requirement.
not publicly verifiable confidence: low
Reviewed public sources did not provide executive compensation, benefit plans, or severance terms.
not publicly verifiable confidence: low
No option-pool, vesting, refresh, or liquidity information was publicly available in reviewed sources.
not publicly verifiable confidence: low
No significant employee-relations problems were verified from reviewed public sources, but private HR and counsel files are needed before drawing a conclusion.
not publicly verifiable confidence: low
Public sources show active hiring but not two-year turnover or retention program effectiveness.
| topic | public signal | diligence implication | source |
|---|---|---|---|
| Named senior departures | No named senior departures were verified in reviewed public sources. | Absence of public proof is not evidence of low attrition; management and acquisition retention must be checked privately. | Reviewed public source set |
| Compensation arrangements | Executive pay, bonus, severance, and benefit-plan detail were not publicly disclosed. | Retention cost and transaction-related liabilities cannot be assessed from public sources. | Reviewed public source set |
| Incentive stock plans and refresh grants | No option pool, vesting, or employee-liquidity detail was publicly available. | Material for dilution, motivation, and common-equity value. | Reviewed public source set |
| Employee relations and turnover | Public sources showed active hiring but no two-year turnover schedule or employee-relations log. | Global scaling risk and acquired-team retention remain opaque. | Careers page and LinkedIn snapshot |
This table intentionally captures disclosure gaps because the checklist topics are mostly private-data items.
Public evidence supports significant regulatory progress and a meaningful IP program, but litigation, insurance, material contracts, and complete legal schedules remain outside public visibility.
not publicly verifiable confidence: low
A limited exact-match CourtListener screen returned no published opinions for the exact brand term, but that is not a substitute for a full litigation search.
| jurisdiction or search | public result | status | caveat |
|---|---|---|---|
| CourtListener exact query “DentalMonitoring” | 0 published opinions returned | No exact-match published US opinion surfaced in this limited screen. | Not a comprehensive docket, claims, or foreign-litigation search; spelling and entity-variant risk remains. |
| Reviewed company pages and public materials | No pending lawsuit schedule disclosed | not_publicly_verifiable | Counsel letters, threatened claims, and settlement schedules were not public. |
Public-source legal screening was narrow and should not be treated as a clean litigation opinion.
not publicly verifiable confidence: low
Reviewed public materials did not reveal a company-initiated litigation schedule, but public silence is not dispositive.
| jurisdiction or search | public result | status | caveat |
|---|---|---|---|
| CourtListener exact query “DentalMonitoring” | 0 published opinions returned | No exact-match published US opinion surfaced in this limited screen. | This does not exclude unreported, foreign, or differently captioned cases, nor demand-letter activity. |
| Reviewed company pages and public materials | No company-initiated litigation schedule disclosed | not_publicly_verifiable | IP enforcement, contract disputes, or threatened claims require counsel confirmation. |
No positive litigation signal was found, but public silence is not dispositive.
partially verified confidence: low
Public materials show some attention to hardware lifecycle and CO2 monitoring, but no public environmental-liability or employee-safety schedule was available.
partially verified confidence: medium
Public materials support a large patent portfolio claim and specific US patents for ScanBox / ScanBox Pro, but not a full trademark, copyright, or license schedule.
| asset or right | jurisdiction or scope | public status | source note |
|---|---|---|---|
| Patent portfolio claim | Global technology and hardware portfolio | 470+ patents filed claimed on patents page and 2026 financing release | Company-maintained figure; reviewed sources did not reconcile granted versus pending across all jurisdictions. |
| US Patent 10,736,715 | United States | Listed as covering DM ScanBox / ScanBox Pro | Named in company virtual patent-marking PDF. |
| US Patent 11,532,079 | United States | Listed as covering DM ScanBox / ScanBox Pro | Named in company virtual patent-marking PDF. |
| US Patent 11,599,997 | United States | Listed as covering DM ScanBox / ScanBox Pro | Named in company virtual patent-marking PDF. |
| Trademark, design, and IP-management framework | Worldwide (self-described) | Code of Conduct says DentalMonitoring is building a strong worldwide trademark, patent, and design portfolio with legal-team oversight. | Self-described governance framework rather than an official registry extract. |
No official patent-office bulk pull or trademark-registry reconciliation was performed in this public-source memo.
not publicly verifiable confidence: low
Insurance coverage was not publicly disclosed despite visible exposure to cyber, product, privacy, and medical-device liabilities.
partially verified confidence: low
Public sources imply material cloud, data-processing, integration, and representative contracts, but not their economics or legal protections.
| contract or exposure | public signal | implication | evidence gap |
|---|---|---|---|
| AWS hosting and cross-border transfer arrangements | Privacy policy names AWS hosting, international server locations, and contractual safeguards for cross-border transfers. | Cloud resilience, DPA terms, and data-localization exposure may be material to enterprise sales and medical-device compliance. | Master cloud agreement, DPA, security addenda, and uptime / incident commitments. |
| BambooHR and data-processing counterparties | Privacy policy references BambooHR and joint-controller roles for some processing purposes. | Cross-border HR and marketing data-processing needs DPA review. | Vendor DPAs, transfer impact assessments, and subprocessors list. |
| Practice-management, manufacturer, and analytics partner agreements | Integration page and Gaidge / Spark references show numerous PMS, manufacturer, and analytics relationships. | Commercial concentration, SLAs, exclusivity, and termination rights are potentially material. | Partner agreements, integration SLAs, economic schedules, and termination/change-of-control clauses. |
| Insurance coverage | Reviewed public sources did not disclose cyber, product-liability, E&O, D&O, or employment-practices policy limits. | Coverage sufficiency against AI, privacy, medical-device, and product claims cannot be assessed publicly. | Insurance schedule, broker letter, claims history, and exclusions summary. |
| Environmental / hardware lifecycle exposure | Code of Conduct says DentalMonitoring monitors CO2 footprint and intends to extend the ScanBox life cycle and reduce components / packaging. | Hardware design, manufacturing, recycling, and lifecycle claims may create ESG and product-obsolescence expectations. | Lifecycle analysis, hardware supplier contracts, take-back / recycling policies, and ESG methodology. |
This table is intentionally exposure-oriented because the underlying contracts and policies were not public.
partially verified confidence: medium
Public sources verify FDA and EU regulatory milestones and compliance-framework claims, but did not surface a public enforcement history or country-by-country exception list.
| agency or framework | action or status | date | public evidence | status |
|---|---|---|---|---|
| U.S. Food and Drug Administration | De Novo DEN230035 granted; regulation 872.1770, product code SBC for DentalMonitoring dental image analyzer. | 2024-05-17 | FDA De Novo database | verified |
| EU MDR / CE marking | DentalMonitoring software announced as certified under EU MDR 2017/745 and CE-marked as a class IIa medical device. | 2024-06-14 | Business Wire certification announcement | verified |
| ISO 13485 / MDSAP | Code of Conduct says DentalMonitoring maintains ISO 13485 and MDSAP coverage across Australia, Brazil, Canada, Japan, and the United States. | 2026-02-24 | Code of Conduct PDF | partially_verified |
| Public enforcement screen | Reviewed sources did not surface a public agency-sanctions or enforcement history tied to the exact brand term. | 2026-06-10 | CourtListener and reviewed public source set | not_publicly_verifiable |
The absence of surfaced enforcement in reviewed sources does not replace a full regulatory correspondence search.
| ID | Claim | Status | Sources |
|---|---|---|---|
| EC-001 | DentalMonitoring says it was founded in 2014, is led by CEO and co-founder Philippe Salah, operates from five global offices, and built its AI platform from over half a billion patient photographs. | verified medium | SRC-001 |
| EC-002 | DentalMonitoring publicly discloses a historical third fundraising round backed by Vitruvian Partners for €45M and also references the acquisition of Loum. | partially verified medium | SRC-001 |
| EC-003 | The DM Difference page says DentalMonitoring serves 8,000+ providers, has scanned 1B+ patient photographs, has filed 200+ patents, employs 170+ developers, scientists, dentists, and orthodontists, and highlights nearly 14,500 app reviews with a 4.9-star rating. | verified medium | SRC-002 |
| EC-004 | DentalMonitoring publicly describes its core platform as AI-powered remote monitoring software with 130+ oral observations, support across treatment phases and appliance brands, and patient messaging / notification workflows. | verified high | SRC-003 |
| EC-005 | DM Engage is publicly positioned as an AI-assisted lead qualification and consultation workflow in which patients upload photos, receive an AI-generated report, and can be converted into virtual or in-practice appointments; one testimonial says it drove 33% more appointments. | partially verified medium | SRC-004 |
| EC-006 | DM Insights is publicly described as an analytics layer showing practice benchmarking, conversion views, patient activity, monitoring status, and messaging analytics. | verified medium | SRC-005 |
| EC-007 | DentalMonitoring says SmartSTL can generate an updated STL remotely using the initial intraoral scan, stage file, and DentalMonitoring scans without requiring an extra in-practice scan for many cases. | verified medium | SRC-006 |
| EC-008 | DentalMonitoring publicly lists a broad workflow ecosystem including Dolphin, Spark, Orthalis, OrthoBridge, OrthoADVANCE, Software 4 Dentists, GreyFinch, TIO, Dentitek, Cloud 4 Ortho, OrthoNovo, and DentoNovo. | verified medium | SRC-007 |
| EC-009 | DentalMonitoring’s evidence library includes company-curated case studies such as Dr. Dabney’s value-per-visit economics and Dr. Audrey Chokron’s 22-month case with 90 scans and only seven in-office visits. | partially verified medium | SRC-008 |
| EC-010 | DentalMonitoring’s evidence library also highlights a 2,248-patient survey across 12 countries and other literature summaries on satisfaction, hygiene detection, periodontitis, and fewer appointments under remote monitoring. | partially verified medium | SRC-008 |
| EC-011 | The Careers page says DentalMonitoring has 400+ employees in 18 countries and shows active hiring across customer care, finance, marketing, product & software, R&D, and sales / implementation. | verified medium | SRC-009 |
| EC-012 | The public LinkedIn profile shows DentalMonitoring with 33,007 followers, 544 listed employees, a 501–1,000 company-size bracket, founding year 2014, headquarters in Paris, and multiple international locations. | verified medium | SRC-010 |
| EC-013 | A 2026 company-sponsored release announced a $100M investment led by Lazard Elaia Capital and ISALT, said DentalMonitoring reached operational profitability in 2025, exceeded 2 million patients and 2 billion images, and had launched a new software development center. | partially verified medium | SRC-011 |
| EC-014 | DentalMonitoring publicly announced that its software is certified under EU MDR 2017/745 and CE-marked as a class IIa medical device. | verified high | SRC-012 |
| EC-015 | DentalMonitoring publicly announced FDA De Novo approval for its software and used the milestone to position SmartSTL and US expansion. | partially verified high | SRC-013 |
| EC-016 | The official FDA De Novo database shows DentalMonitoring (DEN230035) was granted on 2024-05-17 for requester dental monitoring sas under regulation 872.1770 and product code SBC. | verified high | SRC-014 |
| EC-017 | The 2021 ScanBox pro launch release supports the existence of proprietary hardware paired with the app for home dental / orthodontic scans and positions the device as applicable across appliance brands. | verified medium | SRC-015 |
| EC-018 | A 2021 partner release said more than 100 practices would be invited to pilot a combined Gaidge and DentalMonitoring smart-practice program. | partially verified medium | SRC-016 |
| EC-019 | An independent Dentistry Online interview described Guy Deeming’s practice using DentalMonitoring across aligner patients, handling roughly 1,800–2,000 NHS starts plus about 1,000 private starts annually, and saving tens of hours per month. | partially verified medium | SRC-017 |
| EC-020 | DentalMonitoring publicly claims 470+ patents filed and separately lists US patents 10,736,715, 11,532,079, and 11,599,997 for DM ScanBox / ScanBox Pro. | partially verified medium | SRC-018SRC-019 |
| EC-021 | The privacy policy identifies Dental Monitoring SAS (RCS 824 001 259) at 75 rue de Tocqueville, Paris, references AWS hosting and BambooHR processing, and names services including DentalMonitoring, DM Engage, and Vision. | verified high | SRC-020 |
| EC-022 | The Information for Use page provides product-use and regulatory framing for the patient scanning workflow, supporting the existence of controlled intended-use instructions around DM App / ScanBox use. | partially verified medium | SRC-021 |
| EC-023 | DentalMonitoring’s 2026 Code of Conduct says the company maintains ISO 13485 and MDSAP coverage, claims EU MDR class IIa and FDA De Novo status, and emphasizes strong IP ownership and legal-team oversight of the patent / trademark / design portfolio. | partially verified medium | SRC-022 |
| EC-024 | DentalMonitoring’s Code of Conduct says the company monitors its CO2 footprint and aims to extend the ScanBox life cycle while reducing components and packaging. | partially verified low | SRC-022 |
| EC-025 | A limited CourtListener exact-match search for “DentalMonitoring” returned zero published opinions. | verified low | SRC-024 |
| EC-026 | Grin’s public site positions it as a virtual-care platform with FDA-registered Grin Scope hardware, Grin Care Specialists, and an AI 3D Treatment Tracker. | verified medium | SRC-025 |
| EC-027 | CandidPro’s provider platform publicly combines a clear aligner system, orthodontist support, at-home monitoring, and a claim that 90% of cases finish with one or fewer refinements. | verified medium | SRC-026 |
| EC-028 | uLab publicly emphasizes aligners, retainers, indirect bonding, hybrid / combo workflows, and in-office manufacturing flexibility. | verified medium | SRC-027 |
| EC-029 | Reviewed public pages for DentalMonitoring, DM Engage, Grin, CandidPro, and uLab did not disclose numeric pricing, instead relying on demo CTAs or qualitative packaging language. | verified medium | SRC-003SRC-004SRC-025SRC-026SRC-027 |
| EC-030 | The reviewed public source set did not reveal top-customer ARR, churn, NRR, severed relationship schedules, supplier spend, or hardware manufacturing counterparties. | not publicly verifiable medium | SRC-007SRC-008SRC-020SRC-023 |
| EC-031 | Public people data is limited to broad workforce and hiring signals; the reviewed sources did not provide a full executive roster, compensation schedule, turnover history, or incentive-plan detail. | not publicly verifiable medium | SRC-009SRC-010 |
| EC-032 | DentalMonitoring’s In the News page discloses that healthcare professional feedback reflects personal experience and that product claims and regulatory status may vary by country. | verified high | SRC-023 |
| EC-033 | Public company materials point to a multi-region commercial footprint through five global offices, support in eight countries / languages, and regional product / representative infrastructure. | partially verified medium | SRC-001SRC-002SRC-021 |
| EC-034 | Public financing disclosures for the historical €45M round and the 2026 $100M investment did not disclose post-money valuation, ownership percentages, security type, board rights, or cap-table impact. | not publicly verifiable medium | SRC-001SRC-010SRC-011 |
| EC-035 | Reviewed public sources did not disclose audited revenue, ARR, gross margin, cash, debt, backlog, or AR aging, leaving only sponsor-stated profitability and adoption signals. | not publicly verifiable high | SRC-001SRC-010SRC-011 |
| EC-036 | Reviewed public company materials did not provide insurance limits, claims history, or comprehensive litigation and material-contract schedules. | not publicly verifiable high | SRC-020SRC-022SRC-023 |
This report is a public-evidence diligence snapshot, not investment advice. Important financial, legal, technical, and contractual facts remain non-public and should be verified directly with management and primary documents before any investment decision.